Introduction
============

Bone is a highly vascularized tissue enriched in large vessels and capillaries. During development of the mammalian skeletal system, osteogenesis is closely connected with the growth of blood vessels [@B1], [@B2]. Blood vessel networks provide access to the delivery of nutrients, oxygen, pluripotent cells and minerals, which is necessary for osteogenesis [@B3]-[@B5]. Recent studies revealed that a distinct capillary subtype called type H, characterized by high expression of the endothelial markers CD31 and endomucin (CD31^hi^Emcn^hi^), couples angiogenesis and osteogenesis [@B6], [@B7]. However, this specific vessel subtype is reduced with ageing, coinciding with reduced osteoprogenitor numbers and loss of bone mass [@B6], [@B8]. Our previous study showed that type H vessels are also decreased in the bone of ovariectomy (OVX)-induced osteoporotic mouse model and platelet-derived growth factor-BB (PDGF-BB) secreted by preosteoclasts can induce type H vessel generation and subsequently stimulate bone formation [@B9], suggesting that increasing the numbers of preosteoclasts and type H vessels are promising therapeutic strategies for osteoporosis.

Harmine, a natural tricyclic β-carboline alkaloid, is widely distributed in plants, animals, as well as in human tissues and body fluids [@B10]. It has a diverse range of biological activities including potent effects on skeletal and central nervous systems [@B11]-[@B15]. Previous studies have indicated that harmine has the ability to inhibit the fusion of preosteoclasts into multinucleated osteoclasts [@B11] and the intraperitoneal administration of harmine is sufficient to suppress bone resorption and prevent bone loss in OVX-induced osteoporotic mice [@B12]. Considering our previous study showing that preosteoclasts are capable of secreting PDGF-BB to stimulate type H vessel formation and thereby to enhance osteogenesis [@B9], we supposed that the promotion of preosteoclast PDGF-BB-induced angiogenesis might be an important mechanism through which harmine prevents osteoporosis.

In this study, we explored whether harmine could augment the ability of RANKL-stimulated osteoclast precursor RAW264.7 cells to promote angiogenesis of endothelial cells *in vitro* by increasing preosteoclast accumulation and PDGF-BB production. *In vivo*, harmine was prepared into an oil-in-water oral emulsion to reduce its side effects on the central nervous system and was then intragastrically administrated to OVX mice to verify the effects of harmine on type H vessel and bone formation. This study was undertaken to determine whether a harmine emulsion can be used as a therapeutic agent for osteoporosis by inhibition of osteoclast formation and promotion of preosteoclast PDGF-BB-induced angiogenesis and subsequent osteogenesis.

Materials and methods
=====================

Cell culture
------------

The macrophage cell line RAW264.7 cells were cultured in high glucose DMEM (Gibco BRL, Grand Island, USA) supplemented with 10% FBS (Gibco) and 1% penicillin-streptomycin (Gibco). Human microvascular endothelial cells (HMECs) were cultured in MCDB131 medium (Gibco) containing 10% FBS (Gibco), 1 µg/mL hydrocortisone (Sigma, St. Louis, MO, USA), 2 mM L-glutamine (Sigma) and 10 ng/mL epidermal growth factor (EGF; Sigma). Cells were cultured at 37 °C in a humidified atmosphere with 5% CO~2~.

Preparation of conditioned media (CM)
-------------------------------------

RAW264.7 cells were seeded into 48-well culture plates at a density of 1.5 × 10^4^/well and treated with 100 ng/mL receptor activator for nuclear factor κB ligand (RANKL) and 3 μg/mL harmine or an equal volume of vehicle (DMSO). Cells cultured in high glucose DMEM supplemented with 10% FBS and an equal volume of DMSO were served as the negative controls (un-induced group). After 6 days of induction, the CM from un-induced, RANKL-treated or RANKL + harmine-treated RAW264.7 cells were harvested and centrifuged at 2000 ×g for 10 min to collect the supernatant, which was stored at -80 °C or used for downstream experiments.

Tartrate-resistant acid phosphatase (TRAP) staining
---------------------------------------------------

Cells were fixed with 4% paraformaldehyde for 10 min, washed three times with distilled water and then stained for TRAP using a commercial kit (Sigma) according to the manufacturer\'s protocol. TRAP^+^ mononuclear cells and multinucleated cells containing at least three nuclei were identified as preosteoclasts and osteoclasts, respectively, and counted under an inverted microscope (Leica DMI6000B, Solms, Germany).

Angiogenesis-related assays *in vitro*
--------------------------------------

To test whether harmine could augment the pre-angiogenic ability of RANKL-stimulated RAW264.7 cells by promoting PDGF-BB production, HMECs were cultured in MCDB131 medium under different treatment conditions: 1) CM^Vehicle^ + IgG group (treated with CM from un-induced RAW264.7 cells and isotype IgG); 2) CM^RANKL^ + IgG group (treated with CM from RANKL-treated RAW264.7 cells and isotype IgG); 3) CM^RANKL\ +\ Harmine^ + IgG group (treated with CM from RANKL + harmine-treated RAW264.7 cells and isotype IgG); 4) CM^RANKL\ +\ Harmine^ + PDGF-BB Ab group (treated with CM from RANKL + harmine-treated RAW264.7 cells and PDGF-BB-neutralizing antibody). To test the direct effect of harmine on the angiogenic activities of endothelial cells, HMECs were treated with 3 μg/mL harmine or vehicle (DMSO). The IgG isotype control antibody was obtained from Abcam (Cambridge, Cambs, Britain). PDGF-BB-neutralizing antibody was purchased from R&D system (Minneapolis, MN, USA).

Tube formation assay
--------------------

HMECs (1.5 × 10^4^ cells per well) were seeded onto Matrigel-coated 96-well plates and cultured in MCDB131 medium under different treatment conditions. 6 h later, cells were observed with an inverted microscope (Leica). All the parameters (total tube length, total loops and total branching points) revealing the ability of HMECs to form tubes were measured by Image-Pro Plus 6 software.

Cell proliferation assay
------------------------

A cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan) was used to test the proliferation of HMECs in accordance with the manufacturer\'s instructions. Briefly, HMECs (5 × 10^3^ cells per well) were seeded onto 96-well plates and cultured in MCDB131 medium under different treatment conditions. The wells without cells served as the blank. Each well was subjected to CCK-8 solution (10 μL per well) on day 1 to day 5, and cells were incubated at 37 °C for 3 h. The absorbance value of each well was measured at 450 nm using a microplate reader (Bio-Rad 680). The culture medium supplemented with CM from different groups, harmine, or vehicle (DMSO) was replenished every day. A growth curve was drawn to evaluate the cell proliferation rate.

Migration assay
---------------

For the scratch wound assay, HMECs were seeded into a 12-well culture plate at a density of 2.0 × 10^5^/well and cultured until confluence. Next, the confluent cells were wounded by scratching the monolayer with a sterile pipette tip under an inverted microscope (Leica). Cells were then incubated in MCDB131 medium under different treatment conditions. Images of the wounds were acquired immediately, 6 h and 12 h later. The rate of migration area was calculated as described previously [@B16]: Migration area (%) = (*A*~0~ - *An*)/*A*~0~ × 100, where *A*~0~ represents the area of initial wound area, and *An* represents the residual area of wound at the metering point.

For the transwell migration assay, HMECs were suspended at a density of 1 × 10^4^/well and loaded into the top chamber of a 24-well, 8 μm pore-size transwell plate (Corning, NY, USA). Then, complete medium containing CM from different groups with PDGF-BB-neutralizing antibody or isotype IgG was added to the lower chamber. After 12 h, un-migrated cells that remained in the upper chambers were removed by wiping the top of the insert membranes with cotton swabs, while the migrated cells that passed through the membrane pores were stained with 0.5% crystal violet for several minutes and counted under an optical microscope (Leica).

Quantitative real-time PCR (qRT-PCR) analysis
---------------------------------------------

Total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA) and cDNA was synthesized from 1 μg of total RNA by using the RevertAid First Strand cDNA Synthesis kit (Fermentas, Burlington, Canada). Next, qRT-PCR was performed using FastStart Universal SYBR Premix ExTaq^TM^ II (Takara Biotechnology, Japan) on an ABI PRISM® 7900HT System (Applied Biosystems, Foster City, USA). Relative gene expression was calculated by the 2^-△△CT^ method and GAPDH was used as reference for normalization. Primer sequences used for qRT-PCR were as follows: *Atp6v0d2*: forward, 5\'-AGCAAAGAAGACAGGGAG-3\', and reverse, 5\'-CAGCGTCAAACAAAGG-3\'; *Ctsk*: forward, 5\'-GCGGCATTACCAACAT-3\', and reverse, 5\'-CTGGAAGCACCAACGA-3\';*Pdgf-bb*: forward, 5\'-CCTCGGCCTGTGACTAGAAG-3\', and reverse, 5\'-CCTTGTCATGGGTGTGCTTA-3\'; *Gapdh*: forward, 5\'-CACCATGGAGAAGGCCGGGG-3\', and reverse, 5\'-GACGGACACATTGGGGGTAG-3\'.

Preparation of harmine emulsion
-------------------------------

Harmine emulsion was prepared by homogenizing 31.7% (v/v) distilled water in 63.2% (v/v) soybean oil with 5.1% (v/v) emulsifier solution (including 3.0% v/v Span 80 and 2.1% v/v Tween 80; HLB=10.59). Briefly, 37.5 g of harmine was dissolved in 19.02 mL soybean oil, followed by the addition of 37.92 mL distilled water, 1.8 mL Span 80 and 1.26 mL Tween 80. After mixing for 7 min at 75 °C, the mixture was passed through a homogenizing apparatus called a colloidal mill (Langtong Machinery Co.,Ltd, Hebei, China) to form uniform, dispersed and small emulsified particles. The emulsion sample was diluted in distilled water at a ratio of 1:3 and photographed under an optical microscope. The mean length diameter was calculated.

Animals and treatments
----------------------

Animal care and experimental procedures were approved by the Animal Research Committee of Central South University. Thirty 12-week-old female C57BL/6 mice (weighing 25-30 g) were used in this study. The mice were randomly and averagely divided into three groups as follows: (1) sham group (served as controls and treated with an equal volume of vehicle); (2) model group (mice subjected to bilateral OVX and treated with vehicle); (3) harmine group (mice underwent OVX and treated with harmine emulsion). Briefly, mice were generally anesthetized and subjected to OVX or a sham operation as described previously [@B9], [@B17], [@B18]. Two weeks later, harmine emulsion (10 mg/kg) was intragastrically administrated to the mice in the harmine group. The mice in the model group and in the sham group were oral gavaged with an equal volume of vehicle (emulsion without harmine). The treatments were conducted daily for 2 months. Bone marrow samples from tibias of mice were collected in heparin and centrifuged at 860 ×g for 10 min to obtain the supernatant, which was stored at -80 °C until analyses. Uteri were isolated and weighed to confirm the success of OVX and femora were collected for further analyses.

Microcomputed tomography (µCT) analysis
---------------------------------------

Femora were dissected from mice, fixed in 4% paraformaldehyde for 48 h and analyzed by Skyscan 1176 (Skyscan, Aartselaar, Belgium). The scanner was set at a voltage of 50 kV, a current of 400 µA and a resolution of 8.88 µm per pixel. A trabecular bone region of interest (ROI) was drawn starting from 0.15 mm proximal to the distal epiphyseal growth plate and extended proximally for 0.4 mm in order to determine the trabecular bone volume fraction (Tb. BV/TV), trabecular thickness (Tb. Th), trabecular number (Tb. N) and trabecular separation (Tb. Sp).

Histological, immunohistochemical, and immunofluorescent analyses
-----------------------------------------------------------------

For histological and immunohistochemical analyses, femora were dissected and fixed in 4% paraformaldehyde for 48 h, decalcified in 10% ethylene diamine tetraacetic acid (EDTA; pH=7.4) for 21 days, dehydrated through graded ethanol of increasing concentration and then embedded in paraffin. Samples were cut into 5 μm thick longitudinally oriented sections and processed for hematoxylin and eosin (H&E) staining, osteocalcin (OCN) immunohistochemistry staining and TRAP staining as described previously [@B9]. Images were acquired with an optical microscope (CX31; Olympus, Hamburg, Germany). Positively stained cells or relative staining intensity were measured in three random visual fields per section, three sections per mouse and three or four mice per group. For H&E and TRAP staining, the numbers of adipocytes per square millimeter of bone marrow area (N/mm^2^), and preosteoclasts or osteoclasts per adjacent bone surface (N/mm) were calculated. TRAP staining kit was purchased from Sigma. OCN antibody and the secondary antibody were obtained from Abcam.

CD31 and Emcn double immunofluorescent staining were performed to evaluate the extent of type H vessel formation and conducted as previously described [@B9]. Briefly, fresh femora were removed and immediately fixed in 4% paraformaldehyde for 4 h, followed by fast decalcification in 18% EDTA for 3 days. Subsequently, the samples were dehydrated in 30% sucrose, embeded in OCT and cut into 30 μm thick longitudinally oriented sections of bone including the metaphysis and diaphysis. Bone sections were then stained with primary antibodies overnight at 4 °C and with the secondary antibodies at room temperature for 1 h. Sections incubated with secondary antibodies alone served as the negative controls. Nuclei were stained with DAPI. Images were acquired with a Leica DMI6000B fluorescence microscope (Solms, Germany). The numbers of type H vessels (HV) and total vessels (TV; positive for Emcn) were determined by three random fields per section, three sections per mouse and four mice per group. The percentages of type H vessels (HV/TV; %) were calculated. Emcn antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, USA). CD31 antibody and all secondary antibodies were obtained from Abcam.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

The concentrations of PDGF-BB and VEGF in the supernatant of bone marrow or in the CM were measured using a commercial Mouse PDGF-BB ELISA Kit (Cusabio, Wuhan, China) and a Mouse VEGF ELISA Kit (Multi Sciences LTD., Hangzhou, China) according to the protocol provided by the manufacturer. The optical density of each well was determined using a microplate reader (Bio-Rad 680, Hercules, USA) set to 450 nm. Wavelength correction was set to 570 nm. The protein concentration for each sample was calculated according to the standard curve.

Statistical analysis
--------------------

All data are presented as mean ± standard deviation (SD). Two tailed Student\'s t-test was used to compare means between two groups. Analyses were performed using GraphPad Prism software and the differences were judged to be statistically significant when *P* \< 0.05.

Results
=======

Harmine increases the number of preosteoclasts and the production of PDGF-BB
----------------------------------------------------------------------------

To examine the effects of harmine on osteoclastogenesis and the production of PDGF-BB, osteoclast precursor cell line RAW264.7 cells were induced by the osteoclastogenic factor RANKL and treated with harmine or vehicle (DMSO) for 7 days. The expression levels of genes responsible for osteoclast terminal differentiation were assessed by qRT-PCR analysis. The results showed that RNAKL treatment caused significant increases in *Atp6v0d2* and *Ctsk* mRNA levels compared with the un-induced group, but the effect was markedly repressed by harmine (**Figure [1](#F1){ref-type="fig"}A-B**). However, *Pdgf-bb* expression was most abundant in harmine-treated cells (**Figure [1](#F1){ref-type="fig"}C**). TRAP staining revealed that RAW264.7 cells cultured with RANKL exhibited a large amount of TRAP^+^ mononuclear preosteoclasts and multinucleated osteoclasts, whereas harmine treatment inhibited osteoclast formation and caused the accumulation of preosteoclasts (**Figure [1](#F1){ref-type="fig"}D-F**). As evidenced by ELISA, the concentration of PDGF-BB in CM from RNAKL-induced cells was much higher than that in the un-induced group, and harmine treatment resulted in a further increase of PDGF-BB production (**Figure [1](#F1){ref-type="fig"}G**). Our results suggest that harmine augments the production of PDGF-BB by increasing the number of preosteoclasts.

Harmine promotes**preosteoclast PDGF-BB-induced angiogenesis**
--------------------------------------------------------------

To test the effects of harmine on preosteoclast-induced angiogenesis, HMECs were incubated with the CM from RAW264.7 cells stimulated by RANKL or RANKL + harmine for a series of angiogenesis-related functional assays. As shown in **Figure [2](#F2){ref-type="fig"}A**, HMECs treated with the CM from RANKL-stimulated RAW264.7 cells formed higher number of capillary tube-like structures on Matrigel compared with those treated with CM from un-induced cells; once the RANKL-induced cells were additionally treated with harmine, the pro-angiogenic effect of their CM was further enhanced. To verify the role of PDGF-BB in this process, PDGF-BB-neutralizing antibodies were added to the CM from RANKL + harmine-stimulated RAW264.7 cells and the CM-induced positive effect on tube formation was markedly reduced (**Figure [2](#F2){ref-type="fig"}A**). Quantitative measurements revealed that the CM from RANKL-stimulated RAW264.7 cells increased the total tube length, total loops and total branching points compared to controls, and the CM from RANKL + harmine group exhibited much stronger pro-angiogenic effect on HMECs (**Figure [2](#F2){ref-type="fig"}B-D**). However, this effect was blocked by neutralizing antibodies against PDGF-BB (**Figure [2](#F2){ref-type="fig"}B-D**). CCK-8 analysis showed that HMEC proliferation was elevated in response to CM from RANKL-induced RAW264.7 cells and the proliferation of HMECs was stimulated to the relatively greatest extent when exposed to CM from RANKL + harmine-treated cells (**Figure [2](#F2){ref-type="fig"}E**). Once PDGF-BB-neutralizing antibodies were added to the CM from RANKL + harmine-treated cells, their positive effect on HMEC proliferation was reduced (**Figure [2](#F2){ref-type="fig"}E**). As evidenced by the transwell assay (**Figure [2](#F2){ref-type="fig"}F-G**) and scratch wound assay (**Figure [2](#F2){ref-type="fig"}H-I**), the CM from the RANKL + harmine group resulted in the greatest increase in HMEC migration compared to all other groups, whereas this effect was attenuated by PDGF-BB inhibition. These findings indicate that harmine has the ability to promote preosteoclast PDGF-BB-induced angiogenesis.

We also assessed the direct effects of harmine on endothelial angiogenesis in order to exclude the impact of the possible residual harmine in CM on endothelial cell function. The results of tube formation assay (**Figure [3](#F3){ref-type="fig"}A-D**), CCK-8 assay (**Figure [3](#F3){ref-type="fig"}E**) and scratch wound assay (**Figure [3](#F3){ref-type="fig"}F-G**) revealed that HMECs cultured with harmine exhibited significantly lower activities in tube formation, proliferation and motility compared with vehicle (DMSO)-treated cells, suggesting that the stimulatory effects of CM from RANKL + harmine-treated RAW264.7 cells on endothelial angiogenesis are not mediated by the residual harmine.

Intragastric administration of harmine emulsion **prevents bone loss in** OVX mice
----------------------------------------------------------------------------------

Previous reports have shown that intraperitoneal injection of harmine suppresses bone resorption *in vivo* [@B12], but also induces significant neurotoxic effects [@B13]-[@B15]. To minimize the undesired side effects, harmine was prepared into oil-in-water oral emulsion for our *in vivo* study. These emulsified particles exhibited a narrow particle size distribution with a mean diameter of 5.02 ± 1.79 μm (**Figure [S1](#SM0){ref-type="supplementary-material"}A-B**). We tested the pharmacokinetics, tissue distribution and toxicities of harmine emulsion administrated intragastrically in normal mice. The results showed that harmine was rapidly eliminated from serum (t~1/2~ = 11.04 min; **Figure [S1](#SM0){ref-type="supplementary-material"}C**) and mainly distributed in stomach, intestine, liver, lung and bone marrow after administration (**Figure [S1](#SM0){ref-type="supplementary-material"}D**). No remarkable differences were found between harmine emulsion- and vehicle-treated mice, including daily behaviors (**Videos S1-2**) and the serum levels of liver (ALT and AST) and kidney (creatinine and BUN) function indicators (**Figure [S2](#SM0){ref-type="supplementary-material"}A-D**). However, the intraperitoneal injection of harmine solution into mice immediately caused serious neurological effects, such as acute uncontrollable action tremors, convulsions and rigidity (**Videos S3-4**). High levels of harmine accumulation in brain tissues in the solution group (**Figure [S1](#SM0){ref-type="supplementary-material"}E**) may be correlated with its neural toxicity. Our results suggest that the oral administration of harmine in an emulsion form reduces the neural toxicity of harmine and may be suitable for use *in vivo*.

To evaluate the effects of harmine emulsion on osteoporosis, OVX mice were generated and intragastrically administrated with harmine emulsion or vehicle (DMSO) for two months. **Figure [4](#F4){ref-type="fig"}A-B** show significantly smaller uterus size and lower uterus weight in OVX mice compared to sham-operated mice, which confirmed the success of OVX. μCT scanning revealed that OVX mice had markedly lower trabecular bone mass in the distal metaphysis of the femur than that in the sham group, but the intragastric administration of harmine to OVX mice attenuated bone loss (**Figure [4](#F4){ref-type="fig"}C**). Quantitative analyses of trabecular bone volume fraction (Tb. BV/TV), trabecular thickness (Tb. Th), number (Tb. N) and separation (Tb. Sp) confirmed the preventive efficacy of harmine on OVX-induced bone loss (**Figure [4](#F4){ref-type="fig"}D-G**). H&E staining showed plenty of fat vacuoles in bone marrow in OVX mice, while harmine treatment prevented the accumulation of fat cells (**Figure [5](#F5){ref-type="fig"}A-B**). Immunohistochemical staining for OCN revealed that osteogenic activity was slightly reduced in OVX mice, but remarkably increased when the OVX mice were treated with harmine (**Figure [5](#F5){ref-type="fig"}C-D**). TRAP staining showed a large number of osteoclasts on the trabecular bone surface in OVX mice. However, significantly reduced numbers of osteoclasts and enhanced numbers of preosteoclasts were observed in harmine-treated OVX mice (**Figure [5](#F5){ref-type="fig"}E-F**), suggesting an inhibitory role of harmine in the differentiation of preosteoclasts into osteoclasts, which was consistent with the results of our *in vitro* study. Our results indicate that the intragastric administration of harmine emulsion effectively protects against OVX-induced osteoporosis.

Intragastric administration of harmine induces type H vessel formation
----------------------------------------------------------------------

Next, CD31 and Emcn immunofluorescence double staining was performed to verify the effects of harmine on type H blood vessel formation. As shown in **Figure [6](#F6){ref-type="fig"}A-B**, OVX mice had a significantly lower proportion of type H vessels in the metaphysis of the femur compared to sham-operated mice, which was consistent with our previous report [@B9]. Surprisingly, the intragastric administration of harmine to OVX mice led to a prominent increase in the percentage of this specific vessel subtype to a similar extent as in sham-operated mice. The bone marrow concentrations of PDGF-BB (**Figure [6](#F6){ref-type="fig"}C**) and VEGF (**Figure [6](#F6){ref-type="fig"}D**), as detected by ELISA, were dramatically decreased in mice who underwent OVX. In contrast, these pro-angiogenic factors in OVX mice treated with harmine emulsion were markedly elevated. These data, along with our *in vitro* results, suggest that the promotion of preosteoclast-induced angiogenesis may be an important mechanism by which harmine prevents bone loss. Since our results showed that harmine treatment enhanced osteogenic differentiation of mesenchymal stem cells (MSCs) *in vitro* (**Figure [S3](#SM0){ref-type="supplementary-material"}**), a direct stimulation of osteogenesis may also contribute to harmine-induced inhibition of bone loss.

Discussion
==========

Osteoporosis is a major chronic disease worldwide in an aging population and frequently leads to fragility fractures, which bring about low quality of life, increased mortality and high healthcare costs [@B19]. Bisphosphonates and denosumab are the most regular drugs for clinical treatment of osteoporosis, which strongly inhibit resorption of bone, but also suppress ossification and angiogenesis, resulting in atypical femoral fractures and osteonecrosis of the jaw [@B19]-[@B21]. Thus, it is required to develop more ideal drugs for the prevention and treatment of osteoporosis. In the present study, we demonstrated that the intragastric administration of harmine emulsion effectively evoked bone-sparing effects in OVX-induced osteoporotic mice, as defined by enhanced trabecular bone mass and osteogenic responses, as well as decreased osteoclast formation, suggesting the potential utility of harmine as a drug for postmenopausal osteoporosis.

The use of harmine as a multi-purpose traditional medicine has been translated into several commercial applications [@B10]. Harmine has many traditional medicinal uses and pharmacological activities such as anti-inflammatory, anti-parasitic and anti-tumor properties [@B10], [@B22]-[@B26]. An investigation on the effect of harmine on osteoclastogenesis of RAW264.7 cells showed that harmine could inhibit RANKL-induced multinucleated osteoclast formation and prevent bone resorption in both cell and bone tissue cultures [@B12]. Intraperitoneal administration with harmine was able to suppress OVX-induced bone loss in mice [@B12]. However, it should be noted that intraperitoneal injection of harmine could cause serious central nervous system side effects [@B13]-[@B15], [@B26], which impede the development of harmine toward wider clinical applications [@B26]. In this study, we generated an oil-in-water harmine emulsion and found that the oral administration of harmine in emulsion form reduced harmine accumulation in the mouse brain. All the mice oral gavaged with harmine emulsion did not demonstrate abnormal neurological behaviors, but the mice intraperitoneally injected with harmine solution showed high levels of harmine accumulation in the brain and exhibited neurotoxic actions immediately*.* Consistently, no signs of neurotoxicity were observed in OVX mice intragastrically administrated with harmine emulsion during the experiments. Following oral administration, certain amounts of harmine were detected in mouse bone marrow, which may explain the bone-protective effects of harmine emulsion on OVX mice. Thus, harmine emulsion may be used as a promising and safer therapeutic agent for osteoporosis, which needs to be verified by clinical trials in the future.

The importance of angiogenesis in the maintenance of bone has been established. Bone formation requires new blood vessel formation and endothelial cell-derived molecular signals [@B3]-[@B5]. The osteogenesis-promoting effect of the bone vasculature in physiological settings was recently attributed to type H blood vessels [@B6], [@B7]. We and others demonstrated that the relative abundance of this distinct vessel subtype is associated with bone formation and bone loss [@B6]-[@B9]. Moreover, we found that PDGF-BB secreted by preosteoclasts could promote formation of the specific vessels to induce the coupling of angiogenesis with bone formation [@B9], suggesting that PDGF-BB may be a potential therapeutic target for osteoporosis.

In the present study, we found that harmine inhibited the fusion of preosteoclasts into osteoclasts, leading to an accumulation of preosteoclasts and a significant increase of secreted PDGF-BB in the CM. As expected, endothelial cells incubated with the CM exhibited remarkably enhanced angiogenic activities, whereas the effects were blocked by addition of the PDGF-BB-neutralizing antibodies. *In vivo*, we found that the number of type H blood vessels and the concentration of bone marrow PDGF-BB in osteoporotic mice were markedly increased after harmine administration. To the best of our knowledge, this study is the first to show that harmine can augment angiogenesis by increasing preosteoclast PDGF-BB activity. However, it should be noted that harmine has the ability to directly regulate angiogenesis. Previous studies reported that direct treatment of harmine could reduce proliferation, migration and tube formation of endothelial cells, as well as inhibit microvessel outgrowth from the rat aortic ring [@B27], [@B28]. Consistently, results from our study also determined that harmine significantly inhibited angiogenic responses of endothelial cells *in vitro*, which seemed to be inconsistent with our *in vivo* results showing that harmine augmented angiogenesis in bone. The paradoxical results suggest that the pro-angiogenic effect of harmine is mediated through an indirect mechanism. The above data, when taken together, indicate that the promotion of preosteoclast PDGF-BB-induced angiogenesis may be a key mechanism by which harmine accelerates bone formation and prevents bone loss induced by OVX.

In this study, we found that exposure of MSCs to harmine enhanced osteogenesis of MSCs *in vitro*. Thus, a direct promotion of osteogenesis may also be an important mechanism by which harmine prevents osteoporosis. However, the detailed molecular mechanism by which harmine promotes osteogenesis was not assessed in our study. Studies have revealed that excessive adipocyte formation in the bone marrow cavity is an important factor in the development of osteoporosis and this occurs due to a shift in the differentiation of MSCs to favour adipocyte formation at the expense of forming osteoblasts [@B29]-[@B32]. Herein, we found that harmine treatment markedly inhibited the accumulation of fat cells in the bone marrow of OVX mice, suggesting that harmine may reverse the differentiation fate of MSCs from adipogenesis to osteogenesis, which requires further investigation.

In summary, our findings demonstrate that the intragastric administration of harmine emulsion facilitates type H blood vessels and bone formation in osteoporotic mice. The underlying mechanism may be the inhibition of osteoclast formation and the promotion of preosteoclast PDGF-BB-induced angiogenesis, as harmine can block the fusion of preosteoclasts into osteoclasts and augment the pro-angiogenic effects of preosteoclasts by increasing PDGF-BB production *in vitro*. Our study suggests that harmine may represent a promising drug for the prevention and treatment of osteoporosis.
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![**Harmine increases the number of preosteoclasts and the production of PDGF-BB. (A-C)** qRT-PCR analysis of *Atp6v0d2*, *Ctsk* and *Pdgf-bb* expression levels relative to *Gapdh* in RAW264.7 cells treated with vehicle (DMSO), RANKL and RANKL + harmine. n = 4 per group. **(D)** Representative images of TRAP staining showing osteoclast and preosteoclast formation from RAW264.7 cells treated with vehicle, RANKL and RANKL + harmine. Scale bar: 50 μm. **(E-F)** Quantification of TRAP^+^ osteoclasts (OCs) and preosteoclasts (POCs). n = 3 per group. **(G)** Detection of PDGF-BB concentration in conditioned media (CM) from RAW264.7 cells treated with vehicle, RANKL and RANKL + harmine by ELISA. n = 5 per group. **\****P* \< 0.05 vs. un-induced group (RAW264.7 cells treated with harmine vehicle DMSO), **^\#^***P* \< 0.05 vs. RANKL group (RAW264.7 cells treated with RANKL + DMSO).](thnov08p2435g001){#F1}

![**Harmine augments the pro-angiogenic effects of preosteoclasts on endothelial cells. (A-D)** Representative images and quantification of tube formation in HMECs stimulated with CM from different groups and PDGF-BB-neutralizing antibody or IgG isotype control antibody. Scale bar: 200 μm. n = 5 per group. **(E)** CCK-8 analysis of HMEC proliferation in different treatment groups. n = 4 per group. **(F-I)** HMEC motility in different treatment groups was evaluated by the transwell migration assay **(F-G)** (Scale bar: 100 μm) and the scratch wound assay **(H-I)** (Scale bar: 200 μm). n = 3 per group. **\****P* \< 0.05 vs. CM^Vehicle^ + IgG group, **^\#^***P* \< 0.05 vs. CM^RANKL^ + IgG group, **^△^***P* \< 0.05 vs. CM^RANKL\ +\ Harmine^ + IgG group.](thnov08p2435g002){#F2}

![**Direct treatment of harmine inhibits endothelial angiogenesis. (A)** Representative images showing tube formation of HMECs on Matrigel. Scale bar: 200 μm. **(B-D)** Total tube length, total loops and total branching points were measured to quantify the ability of HMECs to form tubes. n = 5 per group. **(E)** Proliferation of HMECs analyzed by the CCK-8 analysis. n = 4 per group. **(F)** Migration of HMECs determined by the scratch wound assay. Scale bar: 200 μm. **(G)** Quantitative analysis of the rate of migration area in (F). n = 3 per group. **\*** *P* \< 0.05 vs. vehicle (DMSO) group.](thnov08p2435g003){#F3}

![**Intragastric administration of harmine emulsion prevents bone loss induced by OVX. (A)** Representative images showing uterine morphology from sham-operated, OVX and OVX mice with harmine treatment. Scale bar: 0.5 cm. **(B)** Uterine weight in different treatment groups. n = 5 per group. **(C-G)** Representative μCT images **(C)** and quantitative μCT analysis **(D-G)** of trabecular bone mass and microarchitecture in femora from sham, OVX and OVX + harmine mice. Scale bar: 1 mm. n = 6-8 per group. **\****P* \< 0.05 vs. sham group, **^\#^***P* \< 0.05 vs. OVX group.](thnov08p2435g004){#F4}

![**Harmine emulsion stimulates osteogenesis and represses osteoclast formation in OVX mice. (A-B)** Representative H&E stained images **(A)** and quantification of adipocytes **(B)** in distal femoral metaphysis regions from sham, OVX and OVX + harmine mice. Blue arrows indicate adipocytes. Scale bar: 50 μm. n = 4 per group. BM: bone marrow. **(C)** Representative images of OCN immunostaining in femora from sham, OVX and OVX + harmine mice. Black arrows indicate OCN-positive areas. Scale bar: 50 μm. **(D)** Quantification of the mean intensity for the OCN immunostaining in different treatment groups. n = 4 per group. **(E)** TRAP staining of femora from sham, OVX and OVX + harmine mice. Red arrows indicate OCs and black arrows indicate POCs. Scale bar: 50 μm. **(F)** Quantification of TRAP^+^ OCs and POCs per bone surface (BS) in different treatment groups. n = 3 per group. **\****P* \< 0.05 vs. sham group, **^\#^***P* \< 0.05 vs. OVX group.](thnov08p2435g005){#F5}

![**Harmine emulsion induces type H vessel formation and PDGF-BB production in OVX mice. (A)** Representative images of CD31 (red) and Emcn (green) immunostaining in femora from sham, OVX and OVX + harmine mice. BM: bone marrow; GP: growth plate; TB: trabecular bone. Scale bar: 100 µm. **(B)** Quantification of the ratio of type H vessel (HV; yellow) in different treatment groups. n = 4 per group. TV: total vessels. **(C-D)** Bone marrow concentrations of PDGF-BB and VEGF from sham, OVX and OVX + harmine mice were detected by ELISA. n = 4 per group. **\****P* \< 0.05 vs. sham group, **^\#^***P* \< 0.05 vs. OVX group.](thnov08p2435g006){#F6}
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